INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10616692	
	Filing Date		2003-07-09	7771474
	First Named Inventor Nelso		elson, Jodi	
	Art Unit		1614	7888888
	Examiner Name	Jone	es, Dwayne C.	
	Attorney Docket Numb	er	47-00B	

			,		U.S.	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Date	Name of Pat of cited Docu	entee or Applicant ument	Relev	es,Columns,Lines when vant Passages or Relev es Appear	e ⁄ant
	1									
If you wisl	h to a	⊥ dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	<u> </u>		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation			s,Columns,Lines where ant Passages or Releves es Appear	ages or Relevant	
•	1									
If you wish	n to ac	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Add	butto	n.	
				FOREI	GN PAT	ENT DOCUM	ENTS			
Examiner Initìal*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Applicant of cited where Relevar		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
	1							17		
If you wish	to ac	l dd additional Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button		L
			NON	-PATE	NT LITE	RATURE DO	CUMENTS			
Examiner Initials*	Cite No	Include name of the au (book, magazine, journ publisher, city and/or o	nal, seria	al, symp	osium,	catalog, etc), o	the article (when a date, pages(s), volu	ppropr ım e -is:	iate), title of the item sue number(s),	T 5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10616692		
Filing Date		2003-07-09		
First Named Inventor Nels		on, Jodi	_	
Art Unit		1614		
Examiner Name Jone		nes, Dwayne C.		
Attorney Docket Number		47-00B		

1	Batchelor, P. E. et al. (1999), "Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor," Journal of Neuroscience, 19(5):1708-1716							
2	Che kapr	Chen, F. Lu et al. (1997), "Calpain Contributes to Silica-Induced I kappa B-alpha Degradation and Nuclear Factor kappa B activation," Arch Biochem Biophysics, 342(2):383-388						
3	Che Brai	Cheng, N. et al. (1996), "Differential Neurotoxicity Induced by L-Dopa and dopamine in Cultured Striatal Neurons," Brain Res, 743(1-2):278-283						
4	Subl	Ebert, M. H. et al. (1984), "Selective Neurotoxic Effects of N-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Subhuman Primates and Man: A New Animal Model of Parkinson's Disease," Psychopharmacology Bulletin, 20 (3):548-553						
5	Kurnick, N. B. et al. (1962), "Reaction Between DNA and Quinacrine and Other Antimalarials," J Lab & Clin Med, 60 (4):669-688							
6	Ladipo, G. O. et al. (1983), "Complete Heart Block in Chronic Chloroquine Poisoning," Int J Cardiol, 4:198-200							
7	Manson, A. J. et al., (2001) "High Dose Naltrexone for Dyskinesias Induced by Levodopa," J. Neurol. Neurosurg. Psychiatry 70:554-556							
8	Zaheer, A. et al., (2001), "Effects of Glia Maturation Factor Overexpression in Primary Astrocytes on MAP Kinase Activation, Transcription Factor Activation, and Neurotrophin Secretion," Neurochem Res, 26(12):1293-1299							
If you wish to a	idd add	litional non-patent literature document citation information please click the Add b	outton					
		EXAMINER SIGNATURE						
Examiner Signature Date Considered								
*EXAMINER: In citation if not in	nitial if confo	reference considered, whether or not citation is in conformance with MPEP 609. rmance and not considered. Include copy of this form with next communication	Draw line through a to applicant.					
¹ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10616692		
Filing Date		2003-07-09		
First Named Inventor Nets		son, Jodi	~~~	
Art Unit		1614		
Examiner Name Jone		es, Dwayne C.		
Attorney Docket Number		47-00B		

CERTIFICATION STATEMENT							
Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):						
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).						
OR	1						
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).						
	See attached cer	rtification statement.					
	Fee set forth in 3	37 CFR 1.17 (p) has been submitted herewith).				
W	None						
SIGNATURE A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.							
Signature		/ellenwinner/	Date (YYYY-MM-DD)	2006-09-01			
Name/Print ELLEN P. WINNER Re			Registration Number	28547			
publ 1.14 appl	This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.						

Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA**

22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
 court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
 negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
 request involving an individual, to whom the record pertains, when the individual has requested assistance from the
 Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.